As Lilly's pharma lineup delivers, cash-cow Elanco sets up for a much-anticipated IPO
admin 24th July 2018 Uncategorised 0Lilly’s animal health unit, Elanco, has been a reliable cash cow since the company bought Novartis’ veterinary unit in 2015. Now, the company plans to spin it off in an IPO, aiming to deliver a payoff to investors and more capital to Lilly’s human health efforts.
More: As Lilly's pharma lineup delivers, cash-cow Elanco sets up for a much-anticipated IPO
Source: fierce